RPRX Stock Analysis: Buy, Sell, or Hold?
RPRX - Royalty Pharma plc Class A Ordinary Shares
$58.61
-0.14 (-0.24%)
âŧ
5d:
-8.25%
30d:
-1.03%
90d:
+6.0%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When RPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: RPRX is fairly priced but lacks strong directional signals. At 4.0% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: RPRX is fairly priced but lacks strong directional signals. At 4.0% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$68.66
Based on 5.6% avg growth
INTRINSIC VALUE TODAY
$42.63
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RPRX is currently trading at $58.61, which is considered slightly low relative to its 30-day fair value range of $58.04 to $62.14. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.2) compared to its historical average (9.1). At these levels, the market is pricing in 4.0% annual earnings growth.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is currently testing key support at $58.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RPRX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $65.12 (+11.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is currently testing key support at $58.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RPRX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $65.12 (+11.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$58.04 -
$62.14
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
Holding RPRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($65.12)
- BULLISH: Expecting earnings turnaround to 4.0% growth with 16.5% revenue growth
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$58.04 -
$62.14
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$58.35
Resistance Level
$64.38
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.22
Wall Street Target
$65.13
(+11.1%)
Revenue Growth (YoY)
16.5%
Earnings Growth (YoY)
-46.3%
Profit Margin
32.0%
Valuation Premium vs History
+4.0% premium
PE vs Historical
10.2 vs 9.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.0%
(market-implied from PE analysis)
1-Year Target
$60.95
(+4%)
2-Year Target
$63.39
(+8%)
3-Year Target
$65.93
(+13%)
3-Yr Target (if PE normalizes)
(PE: 10â9)
PE COMPRESSION
$58.69
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 7.3%)
$142.95
(+144%)
Base:
(SPY PE: 10.2, Growth: 7.3%)
$72.44
(+24%)
Bear:
(PE: 8.7, Growth: 7.3%)
$61.58
(+5%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 32.64 | Current EPS (TTM): $1.80
Bull Case
$129.25
(+121%)
Analyst growth 100.0%, PE expands to 35.9
Base Case
$117.50
(+101%)
Market implied 100.0%, PE stable at 32.6
Bear Case
$39.95
(-32%)
Severe decline -20.0%, PE contracts to 27.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 7:05 PM ET
Data refreshes hourly during market hours. Next update: 8:05 PM
Data refreshes hourly during market hours. Next update: 8:05 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Terrance P Coyne
SELL
34791 shares
2026-04-01
Terrance P Coyne
SELL
34791 shares
2026-03-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
Advanced RPRX Option Strategies
Professional options setups generated by AI based on today's RPRX price and gamma walls.
